Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression

Phase 2

Completed

• Conditions: Major Depressive Disorder
• Interventions: Drug: Esketamine DPI - high dose; Drug: Placebo DPI; Drug: Esketamine DPI - medium dose; Drug: Esketamine DPI - low dose

• Registration Number: NCT03965858
• Lead Sponsor: Celon Pharma SA

Brief Summary

The purpose of the study is to determine the efficacy, safety and pharmacokinetics of inhaled Esketamine in participants with treatment-resistant depression (TRD) in the course of Major Depressive Disorder (MDD). The study is to determine the efficacy and dose response of three Esketamine doses, compared with placebo.

Detailed Description

This is a randomized, multiple dose, placebo-controlled, double-blind, multicentre study of Esketamine DPI, inhalation powder delivered via dry powder inhaler (DPI) in participants with TRD in the course of MDD. There are 3 study phases: Screening phase, a two weeks double-blind treatment phase and a 6-week follow-up phase. Participants are to be randomized in 1:1:1:1 ratio to receive placebo or one of the three doses of Esketamine DPI. Participants from each group will receive different dosing sequences, consider as a single dose, corresponding to low, medium, high Esketamine dose or placebo. Participants will undergo one cycle of treatment consisting of four doses of Esketamine DPI or placebo over 14-day period. Participants safety will be monitored throughout the study.

Study Timeline

• Study Start: 2019-02-25
• Study First Submitted: 2019-05-21
• Study First Submitted QC: 2019-05-26
• Study First Posted: 2019-05-29
• Primary Completion: 2020-03-15
• Status Verified: 2020-04
• Study Completion: 2020-04-24
• Last Update Submitted: 2020-04-27
• Last Update Posted: 2020-04-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 88

Inclusion Criteria

1. Gender: female or male,
2. Age: 18 - 65 years old, inclusive, on the day of Screening,
3. Participant must meet Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) diagnostic criteria for major depressive disorder, without psychotic features, confirmed by the Mini International Neuropsychiatric Interview (MINI),
4. Participant must have in Montgomery-Asberg Depression Rating Scale (MADRS) total score of >= 25 at Screening and predose on Day 1,
5. Participant is treatment resistant, defined as having an inadequate response to at least 2 antidepressants administered for the sufficient duration and dose, both in the current episode of depression,
6. Participant must be on stable monotherapy with antidepressant drug (listed in the protocol) remain non-responsive to it and continue on non-investigational antidepressant therapy from Screening to at least the duration of the double-blind treatment phase,
7. Participant agrees to be hospitalized voluntarily for a period of 12 h before first administration and until the Day 6 of treatment phase. Hospitalization from Day 6 up to the end of treatment phase on Day 14 is up to Investigator discretion, with exception of mandatory hospitalization from 12 h before each administration until 24 h post each administration and from evening on Day 13 until the end of examinations on Day 14,
8. Participant must be medically stable on the basis of clinical laboratory tests, physical examination, vital signs, 12-lead ECG,
9. Participant agrees to blood sample collection for DNA analysis,
10. Participant of childbearing potential willing to use acceptable forms of contraception.

Read More

Exclusion Criteria

1. Participant has a current DSM-5 diagnosis, according to MINI, of any other than MDD disorder,
2. Participant has suicidal ideation in MADRS 'suicidal thoughts' subscale score greater or equal to 2 and/or in C-SSRS score greater or equal to 4 at Screening and/or has a history of suicidal thoughts within 6 months prior to Screening and/or history of suicidal attempt within 1 year prior to Screening,
3. Participant has a history or current signs and symptoms of chronic obstructive pulmonary disease (COPD), asthma, liver or renal insufficiency, significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, hematologic, neurologic, rheumatologic or metabolic disturbances that are uncontrolled with medication change during last three months before Screening and/or that could influence the present general health condition at the Investigator's discretion,
4. Participant has uncontrolled hypertension,
5. Upper respiratory tract and/or chest infection and/or inflammation within 2 weeks preceding the first administration and during the treatment phase,
6. Participant took part in other clinical trial within 90 days preceding the Screening,
7. Known allergy or hypersensitivity, intolerance or contraindication to Esketamine/ketamine or its derivatives and/or to any study product excipients,
8. Blood drawn within 30 days prior to inclusion to the study,
9. History of drug, alcohol, chemical, sedatives or sleeping medications abuse or dependence (except nicotine or caffeine) within 2 years prior to Screening,
10. Lifetime abuse or dependence on ketamine or phencyclidine,
11. Positive results from pregnancy test for female participants,
12. Lactation in female participants,
13. Positive drug screen (except benzodiazepines evaluation during follow-up) or alcohol breath test.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Esketamine high dose	Esketamine DPI - high dose	Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).
Placebo	Placebo DPI	Participants are to receive four doses of Placebo DPI administered over 14-day period (on Day 1, 4, 8 and 11).
Esketamine medium dose	Esketamine DPI - medium dose	Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).
Esketamine low dose	Esketamine DPI - low dose	Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).

Primary Outcome Measures

Name	Time	Method
Change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) total score at Day 14	Day 1 and Day 14	The MADRS is a clinician-rated scale designed to measure depression severity and detect changes due to antidepressant treatment. The test consists of 10 items, each scored from 0 (symptoms not present or normal) to 6 (severe or continuous presence of the symptoms). Total score is 60. The higher MADRS total score, the more severe depression.

Secondary Outcome Measures

Name	Time	Method
Changes between predose and postdose values for each administration in SpO2 (blood oxygen saturation)	up to 2 hours following the start of each administration
Change from baseline in MADRS total score at each other than Day 14 timepoint	Day 1, 2, 4, 5, 8, 9, 11, 12 and week 3, 4, 5, 6, 7 and 8	The MADRS is a clinician-rated scale designed to measure depression severity and detect changes due to antidepressant treatment. The test consists of 10 items, each scored from 0 (symptoms not present or normal) to 6 (severe or continuous presence of the symptoms). Total score is 60. The higher MADRS total score, the more severe depression.
Number of participants with clinical response (>= 50% decrease in MADRS baseline score)	Day 1, 2, 4, 5, 8, 9, 11, 12, 14 and up to 6 weeks after the treatment phase	Clinical response is to be defined as greater than or equal to 50 % decrease in MADRS baseline score at Day 14 and every other timepoint.
Onset of clinical response that was sustained through the end of the 2-week, double-blind, treatment phase	Day 1, 2, 4, 5, 8, 9, 11, 12, 14
Change from baseline in depression severity, measured by Hamilton Depression Rating Scale (HDRS) at every timepoint	Day 1, 2, 4, 5, 8, 9, 11, 12, 14 and week 3, 4, 5, 6, 7 and 8	HDRS is a questionnaire used to rate the severity of depression by probing mood, feelings of guilt, suicide ideation, insomnia, agitation or retardation, anxiety, weight loss and somatic symptoms. HDRS consists of 17 questions with maximum 4-points scale. The higher HDRS total score, the more severe depression.
Time to relapse	Day 14 and week 3, 4, 5, 6, 7 and 8	Relapse assessed for responders and remitters and defined when MADRS total score in 2 consecutive assessments after Day 14 exceeds 50% MADRS baseline total score value.
Number of participants with clinical remission (MADRS total score <= 10)	Day 1, 2, 4, 5, 8, 9, 11, 12, 14 and up to 6 weeks after the treatment phase	Clinical remission, defined as MADRS total score less than or equal to 10.
Change from baseline in Clinical Global Impression - Severity (CGI-S) score at Day 14 and every other timepoint	Day 1, 2, 4, 5, 8, 9, 11, 12, 14 and week 3, 4, 5, 6, 7 and 8	CGI-S scale is a physician-rated scale that is designed to rate the severity of the patient's illness at the time of assessment. It is a 7-point assessment where 1 = normal (not at all ill) and 7 = among the most extremely ill patients.
Change from baseline in Columbia Suicide Severity Rating Scale (C-SSRS) at Day 14 and every other timepoint	Day 1, 14 and week 5, 8	C-SSRS is a suicide ideation rating scale created by researchers at Columbia University.
Change from baseline in the Clinician Administered Dissociative States Scale (CADSS) at each day of administration	up to 24 hours following the start of each administration	CADSS is a scale designed to assess dissociative symptoms. CADSS consists of 23 questions with 4-points scale, where 1=normal (not at all) and 4=Extremely. The higher CADSS total score, the more severe symptoms.
Change from baseline in the Brief Psychiatric Rating Scale (BPRS) at each day of administration	up to 24 hours following the start of each administration	BPRS is a scale designed to rate psychotomimetic effects. BPRS consists of 18 questions with 7-points scale, from 1 (not present) to 7 (extremaly severe). The higher BPRS total score, the more severe effects.
Potential withdrawal symptoms after Esketamine treatment, as measured by the 20-item Physician Withdrawal Checklist (PWC-20)	Day 0, week 3, 4 and 5	PWC-20 is a method to assess discontinuation symptoms.
Potential Esketamine effect on cognition as measured by Montreal Cognitive Assessment (MoCA)	Day 0, week 4 and 8	MoCA is a screening assessment for detecting cognitive impairment.
Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)	up to 8 weeks
Esketamine AUC0-24h - area under the plasma concentration - time curve from time 0 to 24 h	up to 24 hours following the start of first and fourth administration
Esketamine Cmax - maximum plasma concentration	up to 24 hours following the start of first and fourth administration
Esketamine AUC0-inf - area under the plasma concentration - time curve from time 0 to infinity	up to 24 hours following the start of first and fourth administration
Esketamine Kel - terminal elimination rate constant	up to 24 hours following the start of first and fourth administration
Esketamine t1/2 - plasma elimination half-life	up to 24 hours following the start of first and fourth administration
Esketamine Tmax - time to reach maximum concentration in plasma	up to 24 hours following the start of first and fourth administration
Esnorketamine AUC0-24h - area under the plasma concentration - time curve from time 0 to 24 h	up to 24 hours following the start of first and fourth administration
Esnorketamine Cmax - maximum plasma concentration	up to 24 hours following the start of first and fourth administration
Esnorketamine Tmax - time to reach maximum concentration in plasma	up to 24 hours following the start of first and fourth administration
Changes between predose and postdose values for each administration in hematology and biochemistry	up to 6 weeks
Changes between predose and postdose values for each administration in vital signs (heart rate, blood pressure, respiratory rate) and urinalysis	up to 8 weeks

Trial Locations

Locations (11)

Mazowieckie Specalistyczne Centrum Zdrowia; 🇵🇱 Pruszkow, Poland

Uniwersytecki Szpital Kliniczny; 🇵🇱 Wroclaw, Poland

Uniwersyteckie Centrum Kliniczne; 🇵🇱 Gdansk, Poland

Wojewodzki Szpital dla Nerwowo i Psychicznie Chorych; 🇵🇱 Swiecie, Poland

Samodzielny Publiczny Psychiatryczny Zaklad Opieki Zdrowotnej; 🇵🇱 Choroszcz, Poland

Szpital Miejski; 🇵🇱 Elblag, Poland

Mazowiecki Szpital i Centrum Diagnostyczne Allenort; 🇵🇱 Warsaw, Poland

Wojewodzki Szpital im. Jana Pawła II; 🇵🇱 Belchatow, Poland

Pabianickie Centrum Medyczne; 🇵🇱 Pabianice, Poland

Gornoslaskie Centrum Medyczne; 🇵🇱 Katowice, Poland

Specjalistyczny Psychiatryczny Zespol Opieki Zdrowotnej; 🇵🇱 Lodz, Poland